<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wu G</submitter><funding>National Natural Science Foundation of China</funding><pagination>11142-11150</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9063016</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(20)</volume><pubmed_abstract>10,11-Methylenedioxy-camptothecin (FL118) is a novel camptothecin analogue that possesses exceptional antitumor efficacy in human tumor xenograft models. The aim of the current study was to develop novel 20-substituted FL118 derivatives coupled with glycosyl-succinic acid esters with improved antitumor efficacy. These FL118 glycoside derivatives were designed, synthesized and their cytotoxicity evaluated in three tumor cell lines (A-549, MDA-MB-231 and RM-1). All of the derivatives showed superior &lt;i>in vitro&lt;/i> cytotoxic activity and were more potent than irinotecan in A549 and MDA-MB-231 cells. In mouse prostate cancer cells RM-1, 10,11-methylenedioxy-camptothecin rhamnoside 11b displayed significant activities with IC&lt;sub>50&lt;/sub> of 48.27 nM. Western blot analysis demonstrated that 11</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Synthesis of novel 10,11-methylenedioxy-camptothecin glycoside derivatives and investigation of their anti-tumor effects &lt;i>in vivo&lt;/i>.</pubmed_title><pmcid>PMC9063016</pmcid><funding_grant_id>U1406403</funding_grant_id><funding_grant_id>U1706213</funding_grant_id><pubmed_authors>Yu R</pubmed_authors><pubmed_authors>Dong X</pubmed_authors><pubmed_authors>Mai X</pubmed_authors><pubmed_authors>Xu Q</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Jiang T</pubmed_authors><pubmed_authors>Wu G</pubmed_authors><pubmed_authors>Hao C</pubmed_authors><pubmed_authors>Liu F</pubmed_authors><pubmed_authors>Lin M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthesis of novel 10,11-methylenedioxy-camptothecin glycoside derivatives and investigation of their anti-tumor effects &lt;i>in vivo&lt;/i>.</name><description>10,11-Methylenedioxy-camptothecin (FL118) is a novel camptothecin analogue that possesses exceptional antitumor efficacy in human tumor xenograft models. The aim of the current study was to develop novel 20-substituted FL118 derivatives coupled with glycosyl-succinic acid esters with improved antitumor efficacy. These FL118 glycoside derivatives were designed, synthesized and their cytotoxicity evaluated in three tumor cell lines (A-549, MDA-MB-231 and RM-1). All of the derivatives showed superior &lt;i>in vitro&lt;/i> cytotoxic activity and were more potent than irinotecan in A549 and MDA-MB-231 cells. In mouse prostate cancer cells RM-1, 10,11-methylenedioxy-camptothecin rhamnoside 11b displayed significant activities with IC&lt;sub>50&lt;/sub> of 48.27 nM. Western blot analysis demonstrated that 11</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Apr</publication><modification>2026-05-31T09:47:46.605Z</modification><creation>2025-02-18T23:57:24.656Z</creation></dates><accession>S-EPMC9063016</accession><cross_references><pubmed>35520228</pubmed><doi>10.1039/c9ra00315k</doi></cross_references></HashMap>